Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
Zealand Pharma A/S (Nasdaq: ZEAL) announced recent transactions in its shares by managerial personnel on May 12, 2022. The Copenhagen-based biotechnology company specializes in innovative peptide-based medicines, with over 10 drug candidates in clinical development. Notably, two products are already available on the market, including V-Go for diabetes treatment. Zealand’s collaborations with Boehringer Ingelheim and AstraZeneca enhance its pipeline, increasing potential patient access to its therapies. Further details were provided in the attached documents.
- Two products on the market, enhancing revenue streams.
- Strong pipeline with over 10 drug candidates in clinical development.
- Collaborations with Boehringer Ingelheim and AstraZeneca could expand market reach.
- None.
Company announcement – No. 19 / 2022
Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities
Copenhagen, DK and Boston, MA, May 12, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons discharging managerial responsibilities.
Please see the attached files.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In the US Zealand markets V-Go®, a basal-bolus insulin delivery option for people with diabetes, and Zegalogue®, (dasiglucagon), the first and only glucagon analogue for the treatment severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. License collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.
For further information, please contact:
Zealand Pharma Investor Relations
Maeve Conneighton
Argot Partners
investors@zealandpharma.com
Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com
Attachments
- 61_220512_Notification_AdamSteensberg_psu
- 62_220512_Notification_IvanMoeller_psu
- 63_220512_Notification_ChristinaSBredal_psu
FAQ
What recent transactions occurred with Zealand Pharma (ZEAL) securities?
What are the key products marketed by Zealand Pharma?
What partnerships does Zealand Pharma have?
How many drug candidates does Zealand Pharma have in development?
